Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.2 EUR | +5.37% | +8.14% | -23.40% |
Apr. 25 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 319 | 530 | 651.7 | 1,309 | 904.6 | 762.9 | - | - |
Enterprise Value (EV) 1 | 296.6 | 487.8 | 626.6 | 1,648 | 904.6 | 730.6 | 711.4 | 672.2 |
P/E ratio | -139 x | -98.4 x | -48.4 x | 33.4 x | 11.9 x | -41.1 x | -316 x | 16.1 x |
Yield | - | - | - | - | - | - | 0.56% | - |
Capitalization / Revenue | 9.41 x | 15.5 x | 17.6 x | 30.8 x | 11.6 x | 12.9 x | 10.2 x | 5.17 x |
EV / Revenue | 8.75 x | 14.3 x | 17 x | 38.8 x | 11.6 x | 12.3 x | 9.48 x | 4.56 x |
EV / EBITDA | -212 x | -101 x | -50.6 x | -104 x | 596 x | -42.5 x | 46 x | 7.91 x |
EV / FCF | -123 x | -86.1 x | -42.1 x | -36.1 x | - | -11 x | -33 x | 20.9 x |
FCF Yield | -0.81% | -1.16% | -2.38% | -2.77% | - | -9.06% | -3.03% | 4.79% |
Price to Book | 6.62 x | 8.57 x | 11.6 x | 3.67 x | - | 1.31 x | 1.32 x | 1.2 x |
Nbr of stocks (in thousands) | 10,000 | 10,000 | 11,047 | 15,130 | 16,039 | 17,660 | - | - |
Reference price 2 | 31.90 | 53.00 | 59.00 | 86.50 | 56.40 | 43.20 | 43.20 | 43.20 |
Announcement Date | 5/18/20 | 5/17/21 | 5/18/22 | 4/27/23 | 4/25/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | 33.9 | 34.23 | 36.96 | 42.5 | 77.7 | 59.32 | 75.02 | 147.4 |
EBITDA 1 | -1.4 | -4.81 | -12.39 | -15.87 | 1.518 | -17.18 | 15.48 | 84.95 |
EBIT 1 | -2.3 | -5.725 | -13.33 | -17.73 | -0.369 | -22.08 | -3.6 | 57.68 |
Operating Margin | -6.78% | -16.73% | -36.07% | -41.72% | -0.47% | -37.21% | -4.8% | 39.12% |
Earnings before Tax (EBT) 1 | -2.291 | -5.923 | -13.47 | 36.6 | 79.07 | -10.08 | 3.675 | 75 |
Net income 1 | -2.293 | -5.926 | -13.48 | 35.99 | 75.8 | -15.97 | 0.325 | 57.02 |
Net margin | -6.76% | -17.31% | -36.46% | 84.69% | 97.55% | -26.91% | 0.43% | 38.68% |
EPS 2 | -0.2293 | -0.5387 | -1.218 | 2.590 | 4.720 | -1.050 | -0.1367 | 2.687 |
Free Cash Flow 1 | -2.403 | -5.662 | -14.88 | -45.64 | - | -66.2 | -21.58 | 32.2 |
FCF margin | -7.09% | -16.54% | -40.26% | -107.39% | - | -111.59% | -28.76% | 21.84% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | 37.9% |
FCF Conversion (Net income) | - | - | - | - | - | - | - | 56.47% |
Dividend per Share 2 | - | - | - | - | - | - | 0.2433 | - |
Announcement Date | 5/18/20 | 5/17/21 | 5/18/22 | 4/27/23 | 4/25/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2023 S1 |
---|---|
Net sales | - |
EBITDA | - |
EBIT | - |
Operating Margin | - |
Earnings before Tax (EBT) | - |
Net income 1 | 1.804 |
Net margin | - |
EPS 2 | 0.1130 |
Dividend per Share | - |
Announcement Date | 8/30/23 |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 339 | - | - | - | - |
Net Cash position 1 | 22.4 | 42.2 | 25.2 | - | - | 32.3 | 51.5 | 90.7 |
Leverage (Debt/EBITDA) | - | - | - | -21.36 x | - | - | - | - |
Free Cash Flow 1 | -2.4 | -5.66 | -14.9 | -45.6 | - | -66.2 | -21.6 | 32.2 |
ROE (net income / shareholders' equity) | -5.63% | -10.2% | -21.7% | 17.5% | - | -3.4% | -0.05% | 9.55% |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share 2 | 4.820 | 6.190 | 5.070 | 23.60 | - | 33.10 | 32.60 | 36.10 |
Cash Flow per Share 2 | - | -0.4600 | -1.280 | -1.380 | - | -1.690 | 0.5000 | 3.630 |
Capex 1 | 0.92 | 0.56 | 0.7 | 26.8 | - | 37.1 | 44.7 | 47.1 |
Capex / Sales | 2.72% | 1.63% | 1.9% | 62.97% | - | 62.58% | 59.58% | 31.95% |
Announcement Date | 5/18/20 | 5/17/21 | 5/18/22 | 4/27/23 | 4/25/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-23.40% | 822M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- FYB Stock
- Financials Formycon AG